Is Morpheus8 FDA Approved? What the Clearance Actually Says

Type the question into a search engine and the answer comes back with unusual confidence. Clinic after clinic, page after page, states that Morpheus8 is FDA approved. Some put it in the opening line. Some put it on a badge.

It is not true, and it is not a small technicality. Morpheus8 has never been FDA approved. It is 510(k) cleared, which is a different thing granted on a different basis, and the cleared wording does not contain a single one of the outcomes the treatment is sold for. If you believed it, that is because it is everywhere and sounds exactly like the reassurance a regulator would give. So here is the paperwork, word for word.

What the clinic pages say, and what the record says

Every claim in the left column appears routinely on UK pages for this treatment. The right column is what the FDA’s own documents say. None of it requires an insider: clearance summaries are published.

Approved and cleared are two different words

The FDA does not use them interchangeably, and the difference is the whole article.

A 510(k) clearance answers a comparison question. The manufacturer names a device already legally on the market, then demonstrates that the new one is substantially equivalent to it. If the regulator agrees, it may be sold. Nobody in that process is asked to show it delivers a result a patient would recognise.

Morpheus8 is regulated as a Class II device under 21 CFR 878.4400, the classification for electrosurgical cutting and coagulation devices, product code GEI. That classification is itself informative: this is not regulated as a cosmetic device but alongside equipment used to coagulate tissue and stop bleeding, which is precisely what the cleared wording goes on to describe.

What the four clearances actually say

Four clearances carry the Morpheus8 name. Here is the cleared indication in each, in the FDA’s own words, American spellings included.

Haemostasis means stopping bleeding. Electrocoagulation means using an electrical current to coagulate tissue. Contraction of soft tissue is the closest any of it comes to the marketing, and it arrived only in 2023.

Now read the list of words that appear nowhere in any of the four. Wrinkles. Rhytides. Skin tightening. Acne scars. Cellulite. Stretch marks. Body contouring. Fat reduction. Not one of them is in a Morpheus8 clearance.

This is not because the FDA refuses cosmetic indications to needling devices on principle. It says openly that it has authorised microneedling devices to improve the appearance of facial acne scars, facial wrinkles and abdominal scars in patients aged 22 and over. Morpheus8 holds no such authorisation. What the device physically does at depth is covered in how Morpheus8 works.

The 2023 expansion ran on pig tissue

Of the four, the 2023 clearance does the marketing work, because contraction of soft tissue can be made to sound like tightening if nobody reads further. So it is worth reading further.

K231790 was a Special 510(k). The soft tissue contraction wording was supported by ex vivo bench data on porcine muscle and fat, that is, coagulation necrosis measured in pig tissue outside a living body, leveraged from the earlier 2020 clearance. In the part of the clearance summary where trial results would sit, the document records one line: Clinical Performance Data: Not Applicable.

No clinical trial data were submitted for that indication expansion at all. That is not an accusation of wrongdoing: the clearance was granted on that basis, which tells you what this pathway accepts, and therefore how much a clearance can be asked to prove.

So when a clinic offers the 2023 wording as evidence that the treatment tightens skin, what sits underneath it is a bench test on pig tissue. Human evidence does exist, and it is a separate question, examined in what the Morpheus8 evidence actually shows.

Two rival devices are cleared for more than Morpheus8 is

Here the usual story inverts, and almost nobody in the UK market mentions it.

Vivace was cleared in April 2021 for electrocoagulation and haemostasis plus the percutaneous treatment of facial wrinkles in Fitzpatrick skin types I to V, at 1 MHz. Profound was cleared in September 2016 for electrocoagulation and haemostasis, for the percutaneous treatment of facial wrinkles, and for improving the appearance of cellulite in Fitzpatrick types I to III, that last indication supported by six-month data.

Morpheus8 holds neither indication.

Two competing devices hold a facial wrinkle indication from the FDA. Morpheus8 holds no wrinkle indication and no cellulite indication, which is the exact opposite of the way the market talks.

Fairness requires the other half of this. InMode announced in July 2024 that Morpheus8 had secured the first and only FDA clearance for soft tissue contraction among fractional radiofrequency microneedling devices, and read narrowly that claim holds up: it is about the contraction wording specifically. What it is not is a claim to being the most broadly cleared device in the category, because on cosmetic indications Morpheus8 is the narrower one. Both things are true at once, and a page quoting the first while omitting the second is telling you half of it. How these devices differ is set out in Morpheus8 compared with the other RF devices.

What the FDA has actually said about this procedure

The most direct thing the regulator has published about radiofrequency microneedling is not a clearance at all.

On 15 October 2025 the FDA issued a safety communication on the potential risks of certain uses of radiofrequency microneedling. It reports burns, scarring, fat loss, disfigurement, nerve damage and the need for surgical repair. It states that these devices should not be used at home and that its evaluation is ongoing. Its framing sentence is the flattest in the document: radiofrequency microneedling is a medical procedure, not a cosmetic treatment. The communication covers the whole class, not this brand alone.

The professional response is worth reading beside it, because it was not a panic. The American Academy of Dermatology answered the next day, stressing that cosmetic treatments may appear simple but performing them safely requires an in-depth understanding of the structure and function of the skin. In December 2025 the American Society for Laser Medicine and Surgery and the American Society for Dermatologic Surgery jointly stated that radiofrequency microneedling performed in appropriate settings is safe and effective, while urging their own members to add those risks to consent forms.

That is the shape of the honest position: not a dangerous machine, and not a beauty appliance either.

Does an American clearance mean anything in the UK?

Not in law. The FDA regulates the United States market, and none of the four clearances above has any legal force in Britain.

Devices placed on the Great Britain market must be registered with the MHRA, and a manufacturer based outside the UK must appoint a UK Responsible Person. Beyond that we cannot give you a number: no MHRA registration record or certificate for Morpheus8 could be confirmed from a primary source, and we would rather say so than guess. No MHRA safety alert specific to radiofrequency microneedling has been identified either.

So when “FDA cleared” appears on a UK clinic page it is doing marketing work rather than legal work: reassurance borrowed from another country’s regulator, describing a clearance that never mentions the outcome you are being sold. Who may legally hold the handpiece here is a separate question, covered in who can legally perform Morpheus8 in the UK.

What a fair answer sounds like

None of this means the device does nothing. It means the regulatory record cannot carry the weight it is constantly asked to carry. A clearance tells you a device was found similar enough to something already on sale. It tells you nothing about a jawline.

The evidence that would tell you something is thinner than the advertising suggests. The flagship datasets appear in journal supplements sponsored by InMode and written by InMode consultants, which does not make their findings wrong but does need saying. The one independent systematic review that excluded industry-funded studies rates the evidence base Level of Evidence 5, and no sham-controlled randomised trial of Morpheus8 has ever been published.

A clinic that tells you the device is cleared rather than approved, and cleared for coagulation and contraction of soft tissue rather than for wrinkles, has read its own paperwork. That is the answer worth looking for. Book a consultation with us and you will get exactly that: what the clearance covers, what the evidence supports, the risks in the FDA’s own words, and an honest view of whether this is the right tool for what is bothering you.